LLY

1,063.12

+0.04%↑

JNJ

208.77

-0.11%↓

ABBV

226.66

+0.74%↑

UNH

333.66

+1.65%↑

AZN

91.6

+0.91%↑

LLY

1,063.12

+0.04%↑

JNJ

208.77

-0.11%↓

ABBV

226.66

+0.74%↑

UNH

333.66

+1.65%↑

AZN

91.6

+0.91%↑

LLY

1,063.12

+0.04%↑

JNJ

208.77

-0.11%↓

ABBV

226.66

+0.74%↑

UNH

333.66

+1.65%↑

AZN

91.6

+0.91%↑

LLY

1,063.12

+0.04%↑

JNJ

208.77

-0.11%↓

ABBV

226.66

+0.74%↑

UNH

333.66

+1.65%↑

AZN

91.6

+0.91%↑

LLY

1,063.12

+0.04%↑

JNJ

208.77

-0.11%↓

ABBV

226.66

+0.74%↑

UNH

333.66

+1.65%↑

AZN

91.6

+0.91%↑

Search

Simulations Plus Inc

Avatud

SektorTervishoid

18.66 1.91

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

18.18

Max

18.7

Põhinäitajad

By Trading Economics

Sissetulek

67M

-681K

Müük

-2.9M

17M

P/E

Sektori keskmine

48.528

76.798

Aktsiakasum

-0.034

Dividenditootlus

0.48

Kasumimarginaal

-3.9

Töötajad

212

EBITDA

327K

5.3M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+9.63% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

0.48%

2.37%

Järgmine tulemuste avaldamine

8. jaan 2026

Turustatistika

By TradingEconomics

Turukapital

47M

391M

Eelmine avamishind

16.75

Eelmine sulgemishind

18.66

Uudiste sentiment

By Acuity

58%

42%

316 / 374 Pingereas Healthcare

Simulations Plus Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

18. dets 2025, 23:54 UTC

Kuumad aktsiad

Stocks to Watch: Nike, Cassava Sciences, KB Home

18. dets 2025, 23:51 UTC

Tulu

Nike Sales Tick Up in 2Q; China Weakness Persists -- Update

18. dets 2025, 23:39 UTC

Suurimad hinnamuutused turgudel

Cassava Sciences Shares Fall After FDA Places Hold on Epilepsy Drug Trial

18. dets 2025, 22:57 UTC

Omandamised, ülevõtmised, äriostud

TikTok Signs Agreement for Sale of U.S. Unit, Axios Reports, Citing a Memo

18. dets 2025, 21:40 UTC

Tulu

Nike Sales Tick Up, But China Weakness Persists

18. dets 2025, 23:45 UTC

Market Talk

Gold Steady, Supported by Fed Rate-Cut Prospects -- Market Talk

18. dets 2025, 23:37 UTC

Market Talk
Tulu

Nike 2Q Results Fail to Convince Investors of Recovery -- Market Talk

18. dets 2025, 23:36 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street's Rally -- Market Talk

18. dets 2025, 23:03 UTC

Omandamised, ülevõtmised, äriostud

Mitsubishi Materials: Impact on Consolidated Results for FY Ending March 2026 Likely to be Immaterial

18. dets 2025, 23:02 UTC

Omandamised, ülevõtmised, äriostud

Mitsubishi Materials: To Acquire 4,448 Common Shares, 13,771 Preferred Shares of Co.

18. dets 2025, 23:00 UTC

Omandamised, ülevõtmised, äriostud

Mitsubishi Materials: Investment to Strengthen Recovery Network in U.S.

18. dets 2025, 22:59 UTC

Omandamised, ülevõtmised, äriostud

Mitsubishi Materials: Investment to Contribute to Expanding Collection Volume of Secondary Raw Material

18. dets 2025, 22:58 UTC

Omandamised, ülevõtmised, äriostud

SpaceX Could Go Public by Merging With EchoStar. It Isn't a Crazy Idea. -- Barrons.com

18. dets 2025, 22:57 UTC

Omandamised, ülevõtmised, äriostud

Mitsubishi Materials: Elemental USA E-Waste Operates E-Waste Recycling Business in U.S.

18. dets 2025, 22:56 UTC

Omandamised, ülevõtmised, äriostud

Mitsubishi Materials: To Acquire Portion of Shares of Elemental USA E-Waste & ITAD

18. dets 2025, 22:55 UTC

Tulu

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18. dets 2025, 21:59 UTC

Tulu

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18. dets 2025, 21:50 UTC

Market Talk
Tulu

Tech, Media & Telecom Roundup: Market Talk

18. dets 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

18. dets 2025, 21:35 UTC

Tulu

FedEx's Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

18. dets 2025, 21:31 UTC

Tulu

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18. dets 2025, 21:15 UTC

Tulu

Nike 2Q Europe, Middle East & Africa Rev $3.39B >NKE

18. dets 2025, 21:15 UTC

Tulu

Nike 2Q Greater China Rev Down 17% >NKE

18. dets 2025, 21:15 UTC

Tulu

Nike 2Q EPS 53c >NKE

18. dets 2025, 21:15 UTC

Tulu

Nike 2Q Apparel Rev $3.91B >NKE

18. dets 2025, 21:15 UTC

Tulu

Nike 2Q Equipment Rev $550M >NKE

18. dets 2025, 21:15 UTC

Tulu

Nike 2Q N Amer Rev $5.63B >NKE

18. dets 2025, 21:15 UTC

Tulu

Nike 2Q Footwear Rev $7.66B >NKE

18. dets 2025, 21:15 UTC

Tulu

Nike 2Q Asia Pacific & Latin America Rev Down 4% >NKE

18. dets 2025, 21:15 UTC

Tulu

Nike 2Q Greater China Rev $1.42B >NKE

Võrdlus sarnastega

Hinnamuutus

Simulations Plus Inc Prognoos

Hinnasiht

By TipRanks

9.63% tõus

12 kuu keskmine prognoos

Keskmine 20.5 USD  9.63%

Kõrge 25 USD

Madal 16 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Simulations Plus Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

5 ratings

2

Osta

3

Hoia

0

Müü

Sentiment

By Acuity

316 / 374 Pingereas Tervishoid

Uudiste sentiment

Tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat